Immune Design Corp. (IMDZ) Expected to Announce Quarterly Sales of $1.50 Million
Wall Street brokerages forecast that Immune Design Corp. (NASDAQ:IMDZ) will post $1.50 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Immune Design Corp.’s earnings, with estimates ranging from $1.45 million to $1.55 million. Immune Design Corp. posted sales of $1.13 million in the same quarter last year, which would indicate a positive year over year growth rate of 32.7%. The company is scheduled to report its next earnings results on Tuesday, August 8th.
According to Zacks, analysts expect that Immune Design Corp. will report full year sales of $1.50 million for the current year, with estimates ranging from $9.92 million to $13.00 million. For the next year, analysts expect that the firm will report sales of $15.01 million per share, with estimates ranging from $10.12 million to $18.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Immune Design Corp..
IMDZ has been the subject of several recent research reports. Jefferies Group LLC upped their price objective on Immune Design Corp. from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, March 8th. Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th. ValuEngine raised Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday. Finally, Zacks Investment Research raised Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, May 18th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMDZ. Trexquant Investment LP purchased a new stake in Immune Design Corp. during the first quarter worth $183,000. Victory Capital Management Inc. increased its stake in Immune Design Corp. by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock worth $13,175,000 after buying an additional 202,149 shares in the last quarter. Oxford Asset Management purchased a new stake in Immune Design Corp. during the fourth quarter worth $565,000. State Street Corp increased its stake in Immune Design Corp. by 8.3% in the fourth quarter. State Street Corp now owns 237,563 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 18,115 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares in the last quarter. 50.47% of the stock is owned by institutional investors.
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 9.65 on Friday. The firm’s market cap is $246.76 million. Immune Design Corp. has a 52-week low of $4.50 and a 52-week high of $9.70. The firm has a 50-day moving average of $6.84 and a 200 day moving average of $6.29.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.